Cleared Traditional

K941170 - VENTANA ANTI-MELANOMA PRIMARY ANTIBODY

K941170 is the FDA 510(k) clearance for VENTANA ANTI-MELANOMA PRIMARY ANTIBODY by Ventana Medical Systems, Inc.. It is a Class 2 Immunology device (product code DEH) cleared through the Traditional 510(k) pathway after a 1135-day FDA review.

K941170 · Ventana Medical Systems, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1997
Decision
1135d
Days
Class 2
Risk

K941170 is an FDA 510(k) clearance for the VENTANA ANTI-MELANOMA PRIMARY ANTIBODY. Classified as Lambda, Antigen, Antiserum, Control (product code DEH), Class II - Special Controls.

Submitted by Ventana Medical Systems, Inc. (Tucson, US). The FDA issued a Cleared decision on April 22, 1997 after a review of 1135 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5550 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Immunology submissions.

View all Ventana Medical Systems, Inc. devices

Submission Details

510(k) Number K941170 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 14, 1994
Decision Date April 22, 1997
Days to Decision 1135 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
1031d slower than avg
Panel avg: 104d · This submission: 1135d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DEH Lambda, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5550
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DEH Lambda, Antigen, Antiserum, Control

All 43
Devices cleared under the same product code (DEH) and FDA review panel - the closest regulatory comparables to K941170.
VENTANA CD45 PRIMARY ANTIBODY
K940583 · Ventana Medical Systems, Inc. · Oct 1997
CHEMMATE LCA
K973393 · Ventana Medical Systems, Inc. · Sep 1997
VENTANA ANTI-S100 PRIMARY ANTIBODY
K941514 · Ventana Medical Systems, Inc. · Apr 1997
ANTI-MUSCLE ACTIN PRIMARY ANTIBODY
K941707 · Ventana Medical Systems, Inc. · Apr 1997
VENTANA ANTI-CD4 PRIMARY ANTIBODY
K941604 · Ventana Medical Systems, Inc. · Feb 1997
VENTANA ANTI-CD8 PRIMARY ANTIBODY
K941784 · Ventana Medical Systems, Inc. · Feb 1997